中国药房2017，Vol.28Issue(33)：4633-4636,4.DOI:10.6039/j.issn.1001-0408.2017.33.07
参松养心胶囊联合依达拉奉治疗脑血管疾病并发脑心综合征的临床观察
Clinical Observation of Shensong Yangxin Capsules Combined with Edaravone in the Treatment of Cere-brovascular Disease Complicated with Cerebrocardiac Syndrome
摘要
Abstract
OBJECTIVE:To observe therapeutic efficacy and safety of Shensong yangxin capsules combined with edaravone in the treatment of cerebrovascular disease complicated with cerebrocardiac syndrome(CCS). METHODS:A total of 128 cerebrovas-cular disease patients with CCS were randomly divided into control group (64 cases) and observation group (64 cases). Control group received routine treatment,observation group was additionally given Shensong yangxin capsule 1.6 g orally,3 times a day+Edaravone injection 30 mg added into 0.9% Sodium chloride solution 250 mL intravenously,2 times a day. Treatment courses of 2 groups lasted for 10 d. Clinical efficacies of 2 groups were observed,and MDA,SOD,catecholamine(NE,E,DA)levels,cT-nI,NIHSS scores,correlation of cTnI level with NIHSS score were also observed before and after treatment. The occurrence of ADR was recorded. RESULTS:Total response rate of nervous system and electrocardio gram in observation group were significant-ly higher than control group,with statistical significance (P<0.05). Before treatment,there was no statistical significance in MDA,SOD,NE,E,DA,cTnI levels or NIHSS scores between 2 groups(P>0.05). After treatment,MDA,NE,E,DA,cTnI levels and NIHSS scores of 2 groups were significantly lower than before,and the observation group was significantly lower than the control group;SOD of 2 groups were significantly higher than before,and the observation group was significantly higher than the antrol group,with statistical significance (P<0.05). cTnI level was positively correlated with NIHSS score (r=0.956,P=0.001). There was no statistical significance in the incidence of ADR between 2 groups(P>0.05). CONCLUSIONS:Based on rou-tine treatment,Shensong yangxin capsules combined with edaravone can significantly improve therapeutic efficacy of cerebrovascu-lar disease patients with CCS,and improve the levels of catecholamine,MDA and SOD without increasing the occurrence of ADR.关键词
脑心综合征/参松养心胶囊/依达拉奉/疗效/安全性Key words
Cerebrovascular disease complicated with cere-bral cardiac syndrome/Shensong yangxin capsule/Edara-vone/Therapeutic efficacy/Safety分类
医药卫生引用本文复制引用
李敬,张俊岭,姜瑞博,李颖,郑群,闫小菊..参松养心胶囊联合依达拉奉治疗脑血管疾病并发脑心综合征的临床观察[J].中国药房,2017,28(33):4633-4636,4.基金项目
河北省医学科学研究重点课题(No.20160326) （No.20160326）
